Eszopiclone Label Updates 2020-2026, Explained
Eszopiclone's label kept its 2019 boxed warning on complex sleep behaviors through 2026, with reinforced sex-based dosing but no urinary retention warning added.
Eszopiclone: Regulatory History
8 source-based articles maintained by the HealthRX.com Editorial Team.
8articles
4topic areas covered
Jul 14, 2025latest review
Eszopiclone: Regulatory History library
Showing 8 of 8 clinical reviews.
Lunesta Compounding Legal Status: FDA Rules, 503A/503B, and What Prescribers Need to Know
Is compounding eszopiclone (Lunesta) legal? A detailed review of FDA approval history, Schedule IV classification, 503A and 503B pharmacy rules, and current regulatory status for prescribers and patients.
Lunesta EMA vs FDA Approach: Why Europe Rejected What America Approved
Eszopiclone (Lunesta) received FDA approval in 2004 but was refused by the EMA in 2009. This article compares both regulatory decisions, the clinical evidence reviewed, dose changes, and what the split means for patients.
Lunesta FAERS Safety Signals: What Post-Market Surveillance Reveals About Eszopiclone
A clinical review of eszopiclone (Lunesta) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including complex sleep behaviors, next-morning impairment, and the 2019 boxed warning.
Lunesta FDA Approval History: Complete Regulatory Timeline
A full breakdown of Lunesta (eszopiclone) FDA approval history, label changes, safety updates, and post-market surveillance data, prepared by the HealthRX.com Editorial Team.
Lunesta Global Regulatory Status: FDA Approval, Label Requirements, and International Standing
A complete guide to eszopiclone (Lunesta) regulatory history across the FDA, DEA, and international agencies, including current label warnings, scheduling, and post-market safety updates.
Lunesta Legal and Patent Challenges: Eszopiclone Regulatory History
A complete timeline of Lunesta (eszopiclone) patent litigation, Paragraph IV ANDA challenges, FDA dose revisions, and generic entry. Covers Hatch-Waxman disputes, safety label changes, and the 2019 boxed warning.
Lunesta Pipeline and Next-Gen: Eszopiclone Regulatory Status, Label Updates, and What Comes After
A clinical review of eszopiclone (Lunesta) regulatory history, current FDA label requirements, post-market safety signals, and next-generation sleep medications in the pipeline.